top of page
Search

OPGx-RDH12 Gene Therapy: First Participant Dosed in Clinical Trial for Rare Inherited Retinal Disease

2 days ago
6 min read

OPGx-RDH12 uses an AAV viral vector to deliver a functional copy of the RDH12 gene to retinal cells. The first participant has received the experimental therapy in a Phase 1/2 clinical trial.


A new gene therapy strategy for a rare inherited disease that can cause progressive vision loss from early childhood has reached an important clinical development milestone. On November 19, 2026, biotechnology company Opus Genetics announced that the first participant had received the experimental therapy OPGx-RDH12, developed to treat Leber congenital amaurosis associated with alterations in the RDH12 gene (RDH12-LCA).


The approach uses an adeno-associated viral (AAV) vector to deliver a functional copy of the RDH12 gene directly to retinal photoreceptor cells, with the aim of preserving their function and slowing the progression of vision loss. This milestone represents another step forward in the investigation of gene therapies targeting inherited retinal diseases, an area in which identifying the genetic alteration responsible for a disease makes it possible to develop specific therapeutic strategies.


What Is RDH12-Associated Leber Congenital Amaurosis?

Leber congenital amaurosis (LCA) is a group of rare inherited disorders affecting the retina and causing severe visual impairment, usually identified during the first years of life. Different genetic alterations can cause the disease. The form associated with the RDH12 gene, in its classic recessive presentation, is linked to pathogenic variants in both copies of the gene, impairing the production or activity of the retinol dehydrogenase 12 protein.


The RDH12 gene is located on chromosome 14 and contains the instructions for producing an enzyme involved in retinoid metabolism. Retinoids are molecules derived from vitamin A that are essential for normal visual function. This enzyme is primarily found in the inner segments of photoreceptor cells, specialized retinal cells responsible for detecting light. One of its functions is to participate in the metabolism of retinal and other related compounds, helping reduce the accumulation of potentially toxic substances in these cells.


When the gene carries pathogenic variants, RDH12 protein activity may be reduced or impaired. As a result, alterations in retinoid metabolism and in the cells' ability to handle potentially toxic compounds may occur, increasing their vulnerability to cellular damage mechanisms. Over time, these processes may contribute to photoreceptor degeneration and progressive loss of visual function.


What Are the Main Symptoms and How Does the Disease Progress?

Clinical manifestations may vary among individuals, but visual impairment generally begins during childhood.


Reported manifestations include:


  • Reduced visual acuity: difficulty seeing fine details and recognizing objects.

  • Difficulty seeing in low-light conditions: impaired visual adaptation in dim environments.

  • Light sensitivity (photophobia): discomfort in response to certain lighting conditions.

  • Nystagmus: involuntary, repetitive eye movements, which may be present in some individuals.

  • Retinal abnormalities: progressive degeneration of retinal structures, including the macular region, detectable through ophthalmological examinations.


Disease progression may begin during the first years of life, with significant impairment of central vision and structural changes that can be observed through examinations such as optical coherence tomography (OCT).


An important consideration is that disease severity and the rate of progression are not necessarily the same for all patients. The clinical presentation depends, among other factors, on the specific genetic variant and its functional consequences.


A study published in 2024 in the journal Investigative Ophthalmology & Visual Science, which followed 46 patients with biallelic RDH12 variants, demonstrated the importance of assessing both retinal structure and visual function over time. The findings also identified relatively preserved retinal regions that may represent relevant targets for future therapeutic interventions.


How Does OPGx-RDH12 Gene Therapy Work?

The strategy developed by Opus Genetics uses an adeno-associated viral (AAV) vector to deliver a functional copy of the RDH12 gene directly to retinal photoreceptor cells. To understand this approach, it is important to distinguish gene replacement from genome editing.


In this case, the goal is not to directly correct the DNA sequence carrying the mutation. Instead, the strategy aims to provide cells with a functional copy of the gene, allowing them to produce the protein required for their normal function.


The development of OPGx-RDH12 involves several key steps:

1. Selection of the therapeutic gene

The strategy uses a functional version of the RDH12 gene, which contains the instructions needed to produce the retinol dehydrogenase 12 enzyme.


2. Use of an AAV vector

Adeno-associated viruses are used as platforms for delivering genetic material. For therapeutic applications, they are modified to carry the genetic sequence of interest without retaining their natural ability to replicate.


3. Delivery of genetic material to the retina

The vector is administered to reach photoreceptor cells. In the OPGx-RDH12 program, the aim is to deliver the functional copy of the gene directly to these cells.


4. Therapeutic gene expression

Once the vector enters the target cells, the therapeutic genetic material can be used by the cellular machinery to produce the RDH12 protein.


5. Potential preservation of cellular function

With the availability of functional protein, the expectation is to improve retinoid metabolism and reduce cellular mechanisms associated with retinal degeneration.


In this way, the therapy aims to address the molecular cause of the disease rather than simply treating its clinical manifestations. It is important to emphasize that delivering a functional copy of the gene does not necessarily mean that photoreceptors that have already been lost can be restored. Therefore, preserving cells that remain viable is an important consideration in the development of this strategy.


What Is Currently Known About the Preclinical Results?

According to Opus Genetics, preclinical studies conducted in cell models and mice demonstrated restoration of RDH12 activity and functional improvements following the experimental approach.

These findings helped support the progression of the program toward clinical evaluation in humans. However, results obtained in experimental models do not guarantee that the same benefits will be observed in patients. Safety, appropriate dosing, vector distribution, and its potential to preserve visual function still need to be investigated in clinical studies.


What Will Be Evaluated in the Clinical Trial?

On October 21, 2026, the U.S. Food and Drug Administration (FDA) cleared Opus Genetics' Investigational New Drug (IND) application for the clinical development of OPGx-RDH12.This authorization allowed the program to advance to clinical investigation in humans. Subsequently, on November 19, the company announced that the first participant had received the experimental therapy. The study will primarily evaluate the safety and tolerability of the approach. Exploratory parameters related to retinal structure and visual function will also be investigated.


The clinical trial is registered under identifier NCT07681778. Classified in the registry as a Phase 1b/2a study, it represents an early stage of investigation of the therapy in humans. This phase is essential for assessing safety and tolerability, identifying potential adverse events, and gathering information to guide the next stages of development.


As of the announcement, the company had only reported that the first participant had received the experimental therapy. No clinical efficacy results have been reported yet. Therefore, OPGx-RDH12 remains experimental and has not been approved for routine clinical use.


What Does This Milestone Mean for Gene Therapy?

The development of OPGx-RDH12 demonstrates how knowledge of the relationship between genetic alterations and cellular mechanisms can guide the development of targeted treatments. In inherited retinal diseases, AAV vectors have been investigated as tools for delivering therapeutic genes directly to the cells responsible for visual function.


An important example of this approach is voretigene neparvovec (Luxturna), which is approved for patients with retinal dystrophy associated with biallelic mutations in the RPE65 gene. Although it uses a similar AAV-mediated gene replacement strategy, it targets a different gene and should not be confused with OPGx-RDH12.


The expansion of research to include other genes associated with retinal degeneration reinforces the potential of genetic medicine to develop therapeutic alternatives for rare diseases that still have significant unmet medical needs.Furthermore, the program highlights the importance of collaboration among biotechnology companies, researchers, healthcare professionals, and patient organizations. The initiative involves the participation of the Global RDH12 Alliance, which brings together organizations supporting families affected by the disease.


The progress of OPGx-RDH12 will depend on the results of subsequent stages of investigation. Nevertheless, the initiation of treatment in humans represents an important milestone in the search for strategies capable of preserving visual function in people with inherited retinal diseases.


Scientific References and Sources

  1. OPUS GENETICS. Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness. November 19, 2026. Official company announcement. Read the original announcement.


  2. OPUS GENETICS. Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness. October 21, 2026. Read the official announcement.


  3. DAICH VARELA, M.; MICHAELIDES, M. RDH12 retinopathy: clinical features, biology, genetics and future directions. Ophthalmic Genetics, v. 43, n. 3, p. 301–306, 2022. DOI: 10.1080/13816810.2022.2062392.


  4. ALEMAN, T. S. et al. Retinal degeneration associated with biallelic RDH12 variants: longitudinal evaluation of retinal structure and visual function in pediatric patients. Investigative Ophthalmology & Visual Science, v. 65, n. 14, 2024. DOI: 10.1167/iovs.65.14.30.


  5. CLINICALTRIALS.GOV. A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-RDH12. Clinical trial identifier: NCT07681778. View the clinical trial record.


OPGx-RDH12 Gene Therapy: First Participant Dosed in Clinical Trial for Rare Inherited Retinal Disease.
OPGx-RDH12 Gene Therapy: First Participant Dosed in Clinical Trial for Rare Inherited Retinal Disease.

 
 
 

Comments


bottom of page